Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00856960 | The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127) | PHASE1 | COMPLETED | 12 | — | — | Jan 1, 2010 | Apr 1, 2010 | Jan 22, 2016 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Aliskiren 600 mg |
| 2 | ACTIVE_COMPARATOR | Aliskiren 150 mg |
| 3 | ACTIVE_COMPARATOR | Losartan 100 mg |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Aliskiren | DRUG | Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period. |
| Comparator: Losartan | DRUG | Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period. |
| Comparator: Placebo to Aliskiren | DRUG | Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period. |
| Comparator: Placebo to Losartan | DRUG | Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period. |
Inclusion Criteria: * Subject is in generally good health * Subject is willing to avoid unaccustomed strenuous exercise during the study * Subject agrees to consume ONLY the study-specified diet during all domiciled periods * Subject has been a non-smoker for at least 3 months prior to study * Subj...